ArticleJournal of cancer research and clinical oncology2011
Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.
Article in Journal of cancer research and clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Meta-analysis of Osteopontin splice variants in cancer.BMC cancer · 2023Pooled it
- What is new in cancer-associated fibroblast biomarkers?Cell communication and signaling : CCS · 2023Review
- Investigation of the Osteopontin isoforms expression in patients with acute myeloid leukemia.Medical oncology (Northwood, London, England) · 2021Article
- New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis.Cancers · 2021Review
- Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.Pathology oncology research : POR · 2021Article
- Osteopontin-4 and Osteopontin-5 splice variants are expressed in several tumor cell lines.Molecular biology reports · 2020Article
- Review
- Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside ChemoresistanceAsian Pacific journal of cancer prevention : APJCP · 2018Review
- Human osteopontin: Potential clinical applications in cancer (Review).International journal of molecular medicine · 2017Review
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.BMC cancer · 2016Article
- The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.OncoTargets and therapy · 2015Article
- OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.International journal of genomics · 2014Article
- Osteopontin is a prognostic biomarker in non-small cell lung cancer.BMC cancer · 2013Article
- Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer.Tuberculosis and respiratory diseases · 2013Article
- Influence of osteopontin silencing on survival and migration of lung cancer cells.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2013Article
- Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.World journal of gastroenterology · 2012Review
- Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.Journal of experimental & clinical cancer research : CR · 2012Article
- Matricellular proteins: a sticky affair with cancers.Journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLung cancer is one of the most malignant tumors and poses a significant threat to human health. Osteopontin (OPN) is a variably expressed, secreted glycophosphoprotein that mediates the growth and metastases of several carcinoma types. In this study, we aimed to understand the role of OPN in lung cancer cell proliferation and invasiveness.
methodsExpression of OPN was examined using an immunohistochemical method in paraffin-embedded sections collected from 49 patients with lung cancer. We silenced OPN expression by lentivirus-mediated OPN-specific small interfering RNA (siRNA) and examined the proliferation and invasiveness of OPN-silenced lung cancer cell (A549) through MTT, BrdU, flow cytometry, and Matrigel assay. In addition, we tested the role of individual OPN splice variants in A549 cell growth and invasion by constructing OPN overexpression lentiviruses.
resultDownregulation of OPN inhibited A549 cell proliferation and in vivo tumor growth, abrogated augmentation of invasion, induced G1-phase cell cycle arrest, and induced cell late apoptosis and necrosis. Moreover, the proliferation and invasiveness was linked to different OPN splice variants, of which OPN-b affected the cell proliferation and OPN-c showed significant correlation with invasion behavior.
conclusionsOur data suggested that OPN served as a potential biomarker for invasive lung cancer and provided new molecular-targeted therapy for lung cancer based on lentivirus-mediated RNA interference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.